A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00667355

Enrollment

Registered

2008-04-28

Start date

2008-02-29

Completion date

2011-01-31

Last updated

2012-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis

Keywords

Ankylosing Spondylitis

Brief summary

To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis

Detailed description

It is reported that the prevalence of Ankylosing Spondylitis (AS) in Japanese patients is extremely lower than that of Caucasians; therefore, a controlled, double-blind study with similar sample size in Western studies for active AS in Japan was not able to be conducted. As a result, this study was conducted with an open-label design to investigate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active AS. The inclusion criteria and primary endpoint measurement (Achieving Assessment in Ankylosing Spondylitis 20 at Week 12) were designed the same as the Western studies for active AS in consideration with the confirmation of Western data. Treatment with adalimumab was to be continued until the approval of adalimumab for AS in Japanese subjects with active AS.

Interventions

BIOLOGICALadalimumab

40 mg or 80 mg every other week, subcutaneous

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

15 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject who meets the definition of Ankylosing Spondylitis based on the Modified New York Criteria, has a diagnosis of active Ankylosing Spondylitis and has had an inadequate response to or intolerance to one or more nonsteroidal anti-inflammatory drugs

Exclusion criteria

* History of cancer, lymphoma, leukemia or lymphoproliferative disease, active TB, HIV * Previously received anti-TNF therapy * Spinal surgery or joint surgery involving joints to be assessed within 2 months prior to the Screening

Design outcomes

Primary

Measure	Time frame	Description
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12	Week 12	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Secondary

Measure	Time frame	Description
Mean Change From Baseline in Nocturnal Pain	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Nocturnal pain assessed by subjects using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = worst possible pain).
Number of Subjects Achieving ASAS 50	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 50 = at least 50% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Number of Subjects Achieving ASAS 70	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 70 = at least 70% improvement (vs. baseline) and an absolute improvement ≥ 30 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Number of Subjects Achieving Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI 50)	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	BASDAI is a validated self assessment tool used to determine disease activity in subjects with Ankylosing Spondylitis (AS). Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) subjects answered 6 questions measuring discomfort, pain, fatigue, and morning stiffness. BASDAI 50 = at least 50% improvement (vs. baseline) in BASDAI.
Mean Change From Baseline in Patient's Global Assessment of Disease Activity	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Subject's assessment of disease activity using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = none and 100 = severe).
Mean Change From Baseline in Total Back Pain	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Subject assessed his/her back pain by using a Visual Analog Scale (VAS) of 0 - 100 mm (0 = no pain and 100 = most severe pain).
Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	BASFI is a validated self assessment tool that determines the degree of functional limitation in AS subjects. Utilizing a VAS of 0-100 mm (0=easy, 100=impossible), subjects answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions.
Mean Change From Baseline in C-Reactive Protein (CRP)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	CRP is a marker of inflammation and measured in mg/dL. A higher level is consistent with inflammation.
Number of Subjects Achieving ASAS 20	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.
Number of Subjects Achieving Assessment in Ankylosing Spondylitis 40 (ASAS 40)	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS = 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 40 = at least 40% improvement (vs. baseline) and an absolute improvement ≥ 20 units on a 0-100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening in remaining domain.
Number of Subjects Achieving Assessment in Ankylosing Spondylitis Partial Remission	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Partial remission is defined as a score of less than 20 units (on a scale of 0-100; 0=no disease activity and 100=high disease activity) in each of the 4 Assessments in Ankylosing Spondylitis (ASAS) domains: patient global assessment of disease activity, pain, function, and inflammation.
Mean Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	BASMI is an objective measure of spinal mobility. The BASMI score is composed of 5 measures: tragus to wall distance, lumbar flexion, cervical rotation, lumbar side flexion, and intermalleolar distance. Each measure was scored 0-2 (0=normal mobility/mild disease involvement, 1=moderate disease involvement, 2=severe disease involvement) to give a final total score ranging from 0 to 10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.
Mean Change From Baseline in Chest Expansion	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Chest expansion is the difference in centimeters between full expiration and full inspiration, measured at the 4th inter-costal space. An increase in chest expansion represents improvement.
Mean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Each domain was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).
Mean Change From Baseline in Swollen Joint Count for 44 Joints (SJC 44)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).
Mean Change From Baseline in Tender Joint Count for 46 Joints (TJC 46)	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	The number of tender or painful joints among 23 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender or painful joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender or painful joints) to 46 (worst possible score; all joints tender or painful).
Mean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire	Baseline, Weeks 12, 24, 48, 72, 96, 120, and Final Visit	SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).
Number of Subjects Achieving Assessment in Ankylosing Spondylitis (ASAS) 5/6.	Weeks 12, 24, 48, 72, 96, 120, and Final Visit	ASAS 5/6 consists of 6 domains: the 4 used in ASAS 20 (patient global assessment of disease activity, pain, function, inflammation) plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). Achieving ASAS 5/6 requires a 20% improvement compared to baseline in ≥ 5 domains (each domain measured on a 0 - 100 scale \[0 = no disease activity; 100 = high disease activity\]).

Countries

Japan

Participant flow

Participants by arm

Arm	Count
Adalimumab Adalimumab 40 mg or 80 mg subcutaneously administered every other week until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan.	41
Total	41

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Adverse Event	5
Overall Study	Lost to Follow-up	1
Overall Study	Other reason was not specified	5

Baseline characteristics

Characteristic	Adalimumab
Age Continuous	37.2 years STANDARD_DEVIATION 12.17
Age, Customized <40 years	25 subjects
Age, Customized >65 years	0 subjects
Age, Customized Between 40 and 65 years	16 subjects
Region of Enrollment Japan	41 subjects
Sex: Female, Male Female	9 Participants
Sex: Female, Male Male	32 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	41 / 41
serious Total, serious adverse events	6 / 41

Outcome results

Primary

Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12

ASAS measures symptomatic improvement in Ankylosing Spondylitis (AS) subjects. ASAS has 4 domains: patient global assessment of disease activity, pain, function, inflammation. ASAS 20 = at least 20% improvement (vs. baseline) and an absolute improvement ≥ 10 units on a 0 - 100 scale (0 = no disease activity; 100 = high disease activity) for ≥ 3 domains, and no worsening (defined as a worsening of ≥ 20% and a net worsening of ≥ 10 units) in the remaining domain.

Time frame: Week 12

Population: For all non-responder imputation (NRI) analyses, subjects with a missing value at a visit were imputed as a non-responder for that visit. Observed cases is based on a total of 40 subjects analyzed (vs. 41 subjects for the study and all other analysis sets) due to 1 subject who discontinued prior to Week 12.

Arm	Measure	Group	Value (NUMBER)
Adalimumab	Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12	Non-responder imputation (NRI), N = 41	30 Subjects
Adalimumab	Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12	Last Observation Carried Forward (LOCF), N = 41	30 Subjects
Adalimumab	Number of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12	Observed Cases, N = 40	30 Subjects

Secondary

Mean Change From Baseline in 36-Item Short Form (SF-36) Questionnaire

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These are summarized in a physical component summary (PCS) and mental component summary (MCS) score. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=lowest level of functioning; 100=highest level of functioning).